502. Telemedicine Service for Evaluation of Pediatric Outpatients at High Risk for Severe COVID-19

BACKGROUND: During the COVID-19 pandemic, neutralizing monoclonal antibody (mAb) products received emergency use authorization for treatment of mild to moderate COVID-19 in high-risk patients. Expert consensus guidance recommended individualized risk assessment when considering mAb therapies in chil...

Descripción completa

Detalles Bibliográficos
Autores principales: Weakley, Kathryn E, Bryant, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678235/
http://dx.doi.org/10.1093/ofid/ofad500.571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678235/
http://dx.doi.org/10.1093/ofid/ofad500.571

Ejemplares similares